Repurposing an Osteoporosis Drug for β Cell Regeneration in Diabetic Patients

Felizitas Schmitz; Sara Roscioni; Heiko Lickert

doi:10.1016/j.cmet.2015.05.024

Repurposing an Osteoporosis Drug for β Cell Regeneration in Diabetic Patients

Felizitas Schmitz, Sara Roscioni, Heiko Lickert

Helmholtz Center Munich

Research output: Contribution to journal › Short survey › peer-review

6 Scopus citations

Abstract

Replenishing the lost or dysfunctional insulin-producing β cell mass in diabetic patients could slow down or reverse disease progression. Kondegowda et al. (2015) now show that osteoprotegerin and denosumab, inhibitors of the receptor activator of the NF-κB Ligand (RANKL) pathway and osteoclast activation, stimulate human β cell proliferation and therefore possess therapeutic potential.

Original language	English
Pages (from-to)	58-59
Number of pages	2
Journal	Cell Metabolism
Volume	22
Issue number	1
DOIs	https://doi.org/10.1016/j.cmet.2015.05.024
State	Published - 7 Jul 2015
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cmet.2015.05.024

Cite this

@article{05010ad1b4ef4fb0ab49777edaa0edcd,

title = "Repurposing an Osteoporosis Drug for β Cell Regeneration in Diabetic Patients",

abstract = "Replenishing the lost or dysfunctional insulin-producing β cell mass in diabetic patients could slow down or reverse disease progression. Kondegowda et al. (2015) now show that osteoprotegerin and denosumab, inhibitors of the receptor activator of the NF-κB Ligand (RANKL) pathway and osteoclast activation, stimulate human β cell proliferation and therefore possess therapeutic potential.",

author = "Felizitas Schmitz and Sara Roscioni and Heiko Lickert",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",

year = "2015",

month = jul,

day = "7",

doi = "10.1016/j.cmet.2015.05.024",

language = "English",

volume = "22",

pages = "58--59",

journal = "Cell Metabolism",

issn = "1550-4131",

publisher = "Cell Press",

number = "1",

}

TY - JOUR

T1 - Repurposing an Osteoporosis Drug for β Cell Regeneration in Diabetic Patients

AU - Schmitz, Felizitas

AU - Roscioni, Sara

AU - Lickert, Heiko

PY - 2015/7/7

Y1 - 2015/7/7

N2 - Replenishing the lost or dysfunctional insulin-producing β cell mass in diabetic patients could slow down or reverse disease progression. Kondegowda et al. (2015) now show that osteoprotegerin and denosumab, inhibitors of the receptor activator of the NF-κB Ligand (RANKL) pathway and osteoclast activation, stimulate human β cell proliferation and therefore possess therapeutic potential.

AB - Replenishing the lost or dysfunctional insulin-producing β cell mass in diabetic patients could slow down or reverse disease progression. Kondegowda et al. (2015) now show that osteoprotegerin and denosumab, inhibitors of the receptor activator of the NF-κB Ligand (RANKL) pathway and osteoclast activation, stimulate human β cell proliferation and therefore possess therapeutic potential.

UR - http://www.scopus.com/inward/record.url?scp=84937522380&partnerID=8YFLogxK

U2 - 10.1016/j.cmet.2015.05.024

DO - 10.1016/j.cmet.2015.05.024

M3 - Short survey

C2 - 26094892

AN - SCOPUS:84937522380

SN - 1550-4131

VL - 22

SP - 58

EP - 59

JO - Cell Metabolism

JF - Cell Metabolism

IS - 1

ER -

Repurposing an Osteoporosis Drug for β Cell Regeneration in Diabetic Patients

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this